Fenobam

Fenobam was studied in the late 1970s and early 1980s as a novel anxiolytic that, unlike benzodiazepines, did not act on GABA-A receptors, and clinical interest lapsed once inconsistent efficacy and some psychostimulant-like effects were noted. Decades later it was recognized as a selective and potent negative allosteric modulator of mGlu5, which reframed it as a mechanistic forerunner of modern mGlu5 anxiolytics ^[1]. Preclinical rescue of fragile X phenotypes by mGlu5 blockade, including work in Fmr1 knockout models, provided the rationale to revisit fenobam for fragile X syndrome ^[1].

A pilot open-label single-dose trial administered 50 to 150 mg of fenobam to twelve adults with fragile X syndrome and found no clinically significant adverse reactions, dose-dependent but variable plasma concentrations, and improvement of at least twenty percent in prepulse inhibition in six of twelve participants, a signal of improved sensorimotor gating ^[2]. Reviews of mGlu5 antagonists for levodopa-induced dyskinesia also list fenobam among the agents with anti-dyskinetic activity in preclinical Parkinson's models, underscoring the breadth of the mGlu5 target ^[3]. Fenobam is thus significant less as a finished drug than as the compound that first linked mGlu5 pharmacology to human anxiolytic and neurodevelopmental effects.

Limited human data, primarily a single-dose pilot, with supportive preclinical evidence

In its 1980s anxiolytic development fenobam showed variable efficacy and occasional stimulant-like or psychotomimetic effects at some doses, which contributed to its shelving. In the modern single-dose fragile X pilot, doses of 50 to 150 mg produced no clinically significant adverse reactions over the observation period. Because human exposure has been limited to short studies, its long-term safety is not established and it remains investigational.

Fenobam was synthesized and studied by McNeil Laboratories in the 1970s as an anxiolytic under the code McN-3377, with early clinical trials in anxiety. When its GABA-independent mechanism could not be explained and results were inconsistent, development stopped. In 2005 to 2009 researchers identified it as an mGlu5 negative allosteric modulator and revived it as a fragile X candidate, culminating in the Berry-Kravis pilot trial that made it the first mGlu5 negative allosteric modulator tested in a human genetic disorder.

Fenobam occupies a special place in metabotropic glutamate pharmacology as the first mGlu5 negative allosteric modulator with human anxiolytic data and the first tested in fragile X syndrome. It is frequently cited in reviews as the historical bridge between old empirically discovered anxiolytics and rationally designed mGlu5 drugs. Among neuroscience researchers it is respected as a landmark tool compound, though it never became a marketed medicine.